|
BRD3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.23839996222375E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.56669999990578E-08 |
| Normal-vs-Stage2 |
2.554300E-04 |
| Normal-vs-Stage3 |
6.54569998204124E-09 |
| Normal-vs-Stage4 |
3.52329998509759E-09 |
| Stage1-vs-Stage2 |
9.207000E-01 |
| Stage1-vs-Stage3 |
1.258410E-01 |
| Stage1-vs-Stage4 |
1.361560E-02 |
| Stage2-vs-Stage3 |
2.718400E-01 |
| Stage2-vs-Stage4 |
8.325900E-02 |
| Stage3-vs-Stage4 |
3.529800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.49699996632569E-09 |
| Normal-vs-AfricanAmerican |
4.457100E-03 |
| Normal-vs-Asian |
1.92952999999996E-05 |
| Caucasian-vs-AfricanAmerican |
5.041800E-01 |
| Caucasian-vs-Asian |
8.671400E-01 |
| AfricanAmerican-vs-Asian |
4.925000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.84389999999557E-07 |
| Normal-vs-Female |
8.02380051290186E-10 |
| Male-vs-Female |
8.298800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.60890000000924E-07 |
| Normal-vs-Age(41-60Yrs) |
1.74630000460141E-08 |
| Normal-vs-Age(61-80Yrs) |
7.10640002399288E-09 |
| Normal-vs-Age(81-100Yrs) |
3.998100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.164800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.232000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.697800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.789400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.149600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.362200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.751870E-02 |
| Classical-VS-Follicular |
4.952300E-02 |
| Classical-VS-Other |
9.131000E-01 |
| Classical-VS-Normal |
1.72889999983106E-07 |
| Tall-VS-Follicular |
5.063800E-01 |
| Tall-VS-Other |
5.143800E-01 |
| Tall-VS-Normal |
8.63000000350667E-08 |
| Follicular-VS-Other |
6.150200E-01 |
| Follicular-VS-Normal |
6.6950999966231E-08 |
| Other-VS-Normal |
5.629800E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.42770000055981E-08 |
| Normal-vs-N1 |
2.53809999684051E-08 |
| N0-vs-N1 |
1.290750E-01 |
|
|
